A mini-update on chronic rhinosinusitis

Abstract

Chronic rhinosinusitis (CRS) is an inflammatory disorder of the paranasal sinuses and the nasal cavity lasting longer than 12 weeks. This disease is a common clinical syndrome with significant monetary burden due to the high costs of medical visits, diagnostic tests, medications, and surgical therapies. CRS without nasal polyposis (CRSsNP) is the most common subtype of CRS, accounting for about 70% of all patients. Other subtypes include CRS with nasal polyposis (CRSwNP) and allergic fungal rhinosinusitis (AFRS). CRSwNP has the worldwide prevalence of 2% to 4% and is often accompanied by type 2 inflammation and asthma as a comorbid condition. Pediatric chronic sinusitis is distinct from adult chronic sinusitis and is currently considered an infectious process, characterized by persistent inflammation representing an exaggerated immune response to an external stimulus. The medical and surgical management of CRS has been remarkably modified in the past two decades. The aim of this study was to present an update on CRS based on the recent years’ literature.

Keywords

Chronic rhinosinusitis / T cells / endotype / phenotype / nasal polyposis

References

[1] Orlandi RR, Kingdom TT, Smith TL, Bleier B, DeConde A, Luong AU, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021; 11: 213-739.

[2] Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012; 50: 1-12.

[3] Wahid NW, Smith R, Clark A, Salam M, Philpott CM. The socioeconomic cost of chronic rhinosinusitis study. Rhinology. 2020; 58: 112-25.

[4] Kim SL, Rank MA, Peters AT. The chronic rhinosinusitis practice parameter. Ann Allergy Asthma Immunol. 2023; 131: 307-10.

[5] Almosnino G, Little RE. Surgical management of rhinosinusitis for the allergist-immunologist. Ann Allergy Asthma Immunol. 2023; 131: 311-6.

[6] Hopp RJ. Do Adult Forms of Chronic Rhinosinusitis Exist in Children and Adolescents? Sinusitis. 2017; 2: 7.

[7] Quintanilla-Dieck L, Lam DJ. Chronic Rhinosinusitis in Children. Curr Treat Options Pediatr. 2018; 4: 413-24.

[8] Snidvongs K, Sangubol M, Poachanukoon O. Pediatric Versus Adult Chronic Rhinosinusitis. Curr Allergy Asthma Rep. 2020; 20: 29.

[9] Loos DDd, Lourijsen ES, Wildeman MAM, Freling NJM, Wolvers MDJ, Reitsma S, et al. Prevalence of chronic rhinosinusitis in the general population based on sinus radiology and symptomatology. J Allergy Clin Immunol. 2019; 143: 1207-14.

[10] Ostovar A, Fokkens WJ, Vahdat K, Raeisi A, Mallahzadeh A, Farrokhi S. Epidemiology of chronic rhinosinusitis in Bushehr, southwestern region of Iran: a GA2LEN study. Rhinology. 2019; 57: 43-8.

[11] Zhang L, Zhang R, Pang K, Liao J, Liao C, Tian L. Prevalence and risk factors of chronic rhinosinusitis among Chinese: A systematic review and meta-analysis. Front Public Health. 2023; 10: 986026.

[12] Wautlet A, Bachert C, Desrosiers M, Hellings PW, Peters AT. The Management of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With Biologics. J Allergy Clin Immunol Pract. 2023; 11: 2642-51.

[13] Lam K, Schleimer R, Kern RC. The Etiology and Pathogenesis of Chronic Rhinosinusitis: a Review of Current Hypotheses. Curr Allergy Asthma Rep. 2015; 15: 41.

[14] Vlaminck S, Acke F, Scadding GK, Lambrecht BN, Gevaert P. Pathophysiological and Clinical Aspects of Chronic Rhinosinusitis: Current Concepts. Front Allergy. 2021; 2: 741788.

[15] Annunziato F, Romagnani C, Romagnani S. The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol. 2015; 135: 626-35.

[16] Tomassen P, Vandeplas G, Zele TV, Cardell L, Arebro J, Olze H, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016; 137: 1449-56.e4.

[17] Stevens WW, Peters AT, Tan BK, Klingler AI, Poposki JA, Hulse KE, et al. Associations Between Inflammatory Endotypes and Clinical Presentations in Chronic Rhinosinusitis. J Allergy Clin Immunol Pract. 2019; 7: 2812-20.e3.

[18] Kato A, Peters AT, Stevens WW, Schleimer RP, Tan BK, Kern RC. Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches. Allergy. 2022; 77: 812-26.

[19] Bachert C, Maurer M, Palomares O, Busse WW. What is the contribution of IgE to nasal polyposis? J Allergy Clin Immunol. 2021; 147: 1997-2008.

[20] Kaech SM, Cui W. Transcriptional control of effector and memory CD8⁺ T cell differentiation . Nat Rev Immunol. 2012; 12: 749-61.

[21] Mittrücker H, Visekruna A, Huber M. Heterogeneity in the differentiation and function of CD8⁺ T cells. Arch Immunol Ther Exp (Warsz). 2014; 62: 449-58.

[22] Schleimer RP. Immunopathogenesis of Chronic Rhinosinusitis and Nasal Polyposis. Annu Rev Pathol. 2017; 12: 331-57.

[23] Bequignon E, Mangin D, Bécaud J, Pasquier J, Angely C, Bottier M, et al. Pathogenesis of chronic rhinosinusitis with nasal polyps: role of IL-6 in airway epithelial cell dysfunction. J Transl Med. 2020; 18: 136.

[24] Zele TV, Gevaert P, Watelet J, Claeys G, Holtappels G, Claeys C, et al. Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis . J Allergy Clin Immunol. 2004; 114: 981-3.

[25] Zhang Y, Gevaert E, Lou H, Wang X, Zhang L, Bachert C, et al. Chronic rhinosinusitis in Asia. J Allergy Clin Immunol. 2017; 140: 1230-9.

[26] Xu X, Reitsma S, Wang DY, Fokkens WJ. Highlights in the advances of chronic rhinosinusitis. Allergy. 2021; 76: 3349-58.

[27] Delemarre T, Holtappels G, Ruyck ND, Zhang N, Nauwynck H, Bachert C, et al. Type 2 inflammation in chronic rhinosinusitis without nasal polyps: Another relevant endotype. J Allergy Clin Immunol. 2020; 146: 337-43.e6.

[28] Klingler AI, Stevens WW, Tan BK, Peters AT, Poposki JA, Grammer LC, et al. Mechanisms and biomarkers of inflammatory endotypes in chronic rhinosinusitis without nasal polyps. J Allergy Clin Immunol. 2021; 147: 1306-17.

[29] Grayson JW, Cavada M, Harvey RJ. Clinically relevant phenotypes in chronic rhinosinusitis. J Otolaryngol Head Neck Surg. 2019; 48: 23.

[30] Hopkins C, Lee SE, Klimek L, Soler ZM. Clinical Assessment of Chronic Rhinosinusitis. J Allergy Clin Immunol Pract. 2022; 10: 1406-16.

[31] Bhattacharyya N, Lee KH. Chronic recurrent rhinosinusitis: disease severity and clinical characterization. Laryngoscope. 2005; 115: 306-10.

[32] Chua AJ, Jafar A, Luong AU. Update on allergic fungal rhinosinusitis. Ann Allergy Asthma Immunol. 2023; 131: 300-6.

[33] Ciporen JN, Lucke-Wold B, Gillham HE, Cua D, Kim J, Akins P. Paramedian Forehead Flap for Repair of Refractory High-Flow Anterior Skull Base CSF Leak. Turk Neurosurg. 2024; 34: 351-7.

[34] Henson JC, Cutler CC, Cole KL, Lucke-Wold B, Khan M, Alt JA, et al. Immunohistochemical Profiling and Staging in Esthesioneuroblastoma: A Single-Center Cohort Study and Systematic Review. World Neurosurg. 2023; 170: e652-65.

[35] Chitsuthipakorn W, Kanjanawasee D, Hoang MP, Seresirikachorn K, Snidvongs K. Optimal Device and Regimen of Nasal Saline Treatment for Sinonasal Diseases: Systematic Review. OTO Open. 2022; 6: 2473974X221105277.

[36] Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. Executive summary of EPOS 2020 including integrated care pathways. Rhinology. 2020; 58: 82-111.

[37] Peters AT, Spector S, Hsu J, Hamilos DL, Baroody FM, Chandra RK, et al. Diagnosis and management of rhinosinusitis: a practice parameter update. Ann Allergy Asthma Immunol. 2014; 113: 347-85.

[38] Liu YF, Richardson CM, Bernard SH, Church CA, Seiberling KA. Antibiotics, steroids, and combination therapy in chronic rhinosinusitis without nasal polyps in adults. Ear Nose Throat J. 2018; 97: 167-72.

[39] Mansi A, Bui R, Chaaban MR. Oral Corticosteroid Regimens in the Management of Chronic Rhinosinusitis. Ear Nose Throat J. 2022; 101: 123-30.

[40] Propel sinus implant premarket approval application letter [Internet]. [cited 2023 Jan 16]. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf10/P100044A.pdf

[41] Brietzke SE, Shin JJ, Choi S, Lee JT, Parikh SR, Pena M, et al. Clinical consensus statement: pediatric chronic rhinosinusitis. Otolaryngol Head Neck Surg. 2014; 151: 542-53.

[42] Vaidyanathan S, Barnes M, Williamson P, Hopkinson P, Donnan PT, Lipworth B. Treatment of chronic rhinosinusitis with nasal polyposis with oral steroids followed by topical steroids: a randomized trial. Ann Intern Med. 2011; 154: 293-302.

[43] Kirtsreesakul V, Wongsritrang K, Ruttanaphol S. Does oral prednisolone increase the efficacy of subsequent nasal steroids in treating nasal polyposis? Am J Rhinol Allergy. 2012; 26: 455-62.

[44] Ecevit MC, Erdag TK, Dogan E, Sutay S. Effect of steroids for nasal polyposis surgery: A placebo-controlled, randomized, double-blind study. Laryngoscope. 2015; 125: 2041-5.

[45] Simmonds JC, Paz-Lansberg M, Scangas G, Metson R. Endoscopic sinus surgery for chronic rhinosinusitis: 22-item Sino-Nasal Outcome Test 5-year results. Int Forum Allergy Rhinol. 2022; 12: 257-65.

[46] Smith TL, Schlosser RJ, Mace JC, Alt JA, Beswick DM, DeConde AS, et al. Long-term outcomes of endoscopic sinus surgery in the management of adult chronic rhinosinusitis. Int Forum Allergy Rhinol. 2019; 9: 831-41.

[47] Chen F, Zuo K, Guo Y, Li Z, Xu G, Xu R, et al. Long-term results of endoscopic sinus surgery-oriented treatment for chronic rhinosinusitis with asthma. Laryngoscope. 2014; 124: 24-8.

[48] Sinha P, Tharakan T, Payne S, Piccirillo JF. Balloon Sinus Dilation Versus Functional Endoscopic Sinus Surgery for Chronic Rhinosinusitis: Systematic Review and Meta-Analysis. Ann Otol Rhinol Laryngol. 2023; 132: 578-88.

[49] Cutler J, Bikhazi N, Light J, Truitt T, Schwartz M ; REMODEL Study Investigators. Standalone balloon dilation versus sinus surgery for chronic rhinosinusitis: a prospective, multicenter, randomized, controlled trial. Am J Rhinol Allergy. 2013; 27: 416-22.

[50] Bikhazi N, Light J, Truitt T, Schwartz M, Cutler J ; REMODEL Study Investigators. Standalone balloon dilation versus sinus surgery for chronic rhinosinusitis: a prospective, multicenter, randomized, controlled trial with 1-year follow-up. Am J Rhinol Allergy. 2014; 28: 323-9.

[51] Piccirillo JF, Payne SC, Rosenfeld RM, Baroody FM, Batra PS, DelGaudio JM, et al. Clinical Consensus Statement: Balloon Dilation of the Sinuses. Otolaryngol Head Neck Surg. 2018; 158: 203-14.

[52] Miglani A, Soler ZM, Smith TL, Mace JC, Schlosser RJ. A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis. Int Forum Allergy Rhinol. 2023; 13: 116-28.

[53] Schalek P, Otruba L, Guha A. Extent of surgery in chronic rhinosinusitis: primarily focused on nasal polyposis. Arch Otolaryngol Rhinol. 2017; 3: 109-14.

[54] Scangas GA, Wu AW, Ting JY, Metson R, Walgama E, Shrime MG, et al. Cost Utility Analysis of Dupilumab Versus Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps. Laryngoscope. 2021; 131: E26-33.

[55] Lans RJLvd, Hopkins C, Senior BA, Lund VJ, Reitsma S. Biologicals and Endoscopic Sinus Surgery for Severe Uncontrolled Chronic Rhinosinusitis With Nasal Polyps: An Economic Perspective. J Allergy Clin Immunol Pract. 2022; 10: 1454-61.

[56] Rathi VK, Scangas GA, Metson RB, Xiao R, Nshuti L, Dusetzina SB. Out-of-pocket costs of biologic treatments for chronic rhinosinusitis with nasal polyposis in the Medicare population. Int Forum Allergy Rhinol. 2022; 12: 1295-8.

[57] Roland LT, Regenberg A, Luong AU, Wise SK, Toskala E, Lam KK, et al. Biologics for chronic rhinosinusitis with nasal polyps: Economics and ethics. Int Forum Allergy Rhinol. 2021; 11: 1524-28.

[58] Fieux M, Rumeau C, Bonnecaze GD, Papon JF, Mortuaire G. Surgery for chronic rhinosinusitis with nasal polyps: An update. Eur Ann Otorhinolaryngol Head Neck Dis. 2023; 140: 297-304.

[59] Blauwblomme M, Gevaert P, Van Zele T. Chronic rhinosinusitis: matching the extent of surgery with pathology or does the extent of surgery matter? Curr Otorhinolaryngol Rep. 2023; 11: 273-85.

[60] Garvey E, Naimi B, Duffy A, Hannikainen P, Kahn C, Farquhar D, et al. Optimizing the timing of biologic and surgical therapy for patients with refractory chronic rhinosinusitis with nasal polyposis (CRSwNP). Int Forum Allergy Rhinol. 2024; 14: 651-9.

[61] Peters AT, Han JK, Hellings P, Heffler E, Gevaert P, Bachert C, et al. Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract. 2021; 9: 2461-71.e5.

[62] Oykhman P, Paramo FA, Bousquet J, Kennedy DW, Brignardello-Petersen R, Chu DK. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis. J Allergy Clin Immunol. 2022; 149: 1286-95.

[63] Chong L, Piromchai P, Sharp S, Snidvongs K, Webster KE, Philpott C, et al. Biologics for chronic rhinosinusitis. Cochrane Database Syst Rev. 2021; 3: CD013513.

[64] Staudacher AG, Peters AT, Kato A, Stevens WW. Use of endotypes, phenotypes, and inflammatory markers to guide treatment decisions in chronic rhinosinusitis. Ann Allergy Asthma Immunol. 2020; 124: 318-25.

[65] Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, et al. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial. JAMA. 2016; 315: 469-79.

[66] Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019; 394: 1638-50.

[67] Gevaert P, Han JK, Smith SG, Sousa AR, Howarth PH, Yancey SW, et al. The roles of eosinophils and interleukin-5 in the pathophysiology of chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2022; 12: 1413-23.

[68] Bachert C, Han JK, Desrosiers MY, Gevaert P, Heffler E, Hopkins C, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial. J Allergy Clin Immunol. 2022; 149: 1309-17.e12.

[69] Le TT, Emmanuel B, Katial R, Tran TN, Kwiatek JJ, Cohen DS, et al. ; RANS Study Investigators. Benralizumab in Severe Eosinophilic Asthma and Chronic Rhinosinusitis with Nasal Polyps: The Real-World, Multi-Country RANS Observational Study. J Asthma Allergy. 2024; 17: 313-24.

[70] Kovalszki A, Weller PF. Eosinophilia. Prim Care. 2016; 43: 607-17.

[71] Aslan F, Altun E, Paksoy S, Turan G. Could Eosinophilia predict clinical severity in nasal polyps? Multidiscip Respir Med. 2017; 12: 21.

[72] OCEAN (depemOkimab effiCacy Eosinophilic grAnulomatosis with polyaNgiitis). c1998-2024 [cited 2024 Jul 3]. Available from: https://www.mayo.edu/research/clinical-trials/cls-20535901

[73] GSK starts the first phase 3 study with a long-acting anti-IL-5 treatment for patients with severe asthma [Internet]. GSK plc. ; c2001- 2024 [cited 2024 Apr 10]. Available from: https://www.gsk.com/en-gb/media/press-releases/gsk-starts-the-first-phase-3-study-with-a-long-acting-anti-il-5-treatment-for-patients-with-severe-asthma/